Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Subscribe|Follow Us On

In Vivo Production of an Anti-HIV Antibody in Mice by Non-Viral Gene Knock-In in Primate Hematopoietic Stem and Progenitor Cells

February 3, 2026

[Molecular Therapy] Researchers evaluated CRISPR/Cas9 and CRISPR/Cas12a for gene knock-in at the immunoglobulin heavy chain locus in non-human primate hematopoietic stem and progenitor cells.

Phf6 Truncating Mutation Drives Leukemogenesis via Disrupted Epigenetic Regulation in Mice

February 3, 2026

[Leukemia] The authors generated a transgenic mouse model, Phf6^R274XTg, expressing a patient-derived truncated Phf6 mutation specifically in hematopoietic lineages.

Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

February 3, 2026

[Blood Cancer Discovery] By reconstructing epigenetic ontogeny in juvenile myelomonocytic leukemia (JMML), investigators identified a postnatal maturation state of JMML stem cells with high transcriptional plasticity indicative of oncofetal reprogramming in high-risk disease.

iPSC-Derived Modeling of HLA-Lacking Hematopoiesis Reveals Clonal Diversity in Eltrombopag Response in Acquired Aplastic Anemia

February 3, 2026

[Stem Cells] Investigators evaluated the hematopoietic effects of eltrombopag using umbilical cord blood-derived hematopoietic progenitor cells and a humanized hematopoiesis model in immunodeficient mice.

Efficacy and Mechanism of Action of Sovleplenib for Aplastic Anemia

February 3, 2026

[Hematology] An immune-mediated aplastic anemia mouse model was established and treated with sovleplenib. Hematopoietic function was assessed via peripheral blood counts and bone marrow mononuclear cell counts.

DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML but Is Associated with Increased Leukemia Stem Cell Frequency

February 3, 2026

[Cancer Discovery] The authors developed CRISPR-based methods to directly correct DNMT3A^R882 mutations in leukemic cells obtained from patients.

Progress of Investigational Bromodomain and Extra-Terminal Domain Inhibitors for Myelofibrosis Therapy

February 3, 2026

[Expert Opinion on Investigational Drugs] The authors summarize the biology, preclinical data, and emerging clinical data in the development of novel bromodomain and extra-terminal domain inhibitor.

Shorla Oncology® Announces US FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T Cell Acute Lymphoblastic Leukemia and...

February 3, 2026

[Shorla Oncology (Businesswire)] Shorla Oncology announced that the US FDA has approved the company’s oncology drug, Nelarabine Injection, in a larger vial size, 375mg/75mL, for adult and pediatric patients with T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma.

Treatment Outcome and Efficacy of Desensitization Strategies for Immunized-PTR in Hematological Malignancies before Hematopoietic Stem Cell Transplantation

January 28, 2026

[Bone Marrow Transplantation] Scientists found that immunized-PTR was associated with poor outcomes in hematological malignancies patients after allogeneic hematopoietic stem-cell transplantation transplantation, and desensitization with rituximab and therapeutic plasma exchange achieved favorable outcomes.

Gpr171 Regulates Embryonic Hematopoietic Stem Cell Emergence via ERK1/2 and Notch Signaling

January 28, 2026

[Proceedings of The National Academy of Sciences of The United States of America] Researchers identifed GPR171, a P2Y-family G-protein-coupled receptor, as a critical regulator of vertebrate embryonic HSC specification.

Comparative Analysis of CRISPR-Cas9, Lentiviral Transduction, and Base Editing for Sickle Cell Disease in a Murine Model

January 28, 2026

[Blood Advances] Base editing and lentiviral transduction provided superior outcomes over CRISPR-Cas9–mediated editing in a competitive murine transplantation model

Caring Cross and Boston Children’s Hospital Collaborate to Expand Access to Gene Therapy for Sickle Cell Disease and Beta Thalassemia

January 28, 2026

[Boston Children's Hospital (EurekAlert)] Caring Cross and Boston Children’s Hospital announced a collaboration to provide a sustainable, affordable pathway for patients to access stem cell gene therapies for the treatment of Sickle Cell Disease.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.